The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1409
February 4, 2013
View Complete Issue         Table of Contents 2019 
Apixaban (Eliquis) - A New Oral Anticoagulant for Atrial Fibrillation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Apixaban (Eliquis) - A New Oral Anticoagulant for Atrial Fibrillation
February 4, 2013 (Issue: 1409)
The FDA has approved apixaban (Eliquis – Bristol-Myers Squibb/Pfizer), an oral direct factor Xa inhibitor, for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is the third new oral anticoagulant to...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Apixaban (Eliquis) - A New Oral Anticoagulant for Atrial Fibrillation
Article code: 1409a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.